Read About the Latest News and Events at DRUGSCAN

DRUGSCAN® to Present Scientific Data at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition HORSHAM, Pa., Nov. 14, 2016 /PRNewswire/ -- DRUGSCAN© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, announced today that their scientists will be presenting data at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition held in Denver Colorado, from CAT.one® laboratory-based studies they conducted to assess the abuse-deterrent features of a polyethylene oxide (POLYOX™) based matrix formulation and the smoke-ability of opioid formulations. The data being presented can help guide developers of abuse-deterrent products. DRUGSCAN® to Present Scientific Data at the PAINWeek 2016 Conference HORSHAM, Pa., Aug. 30, 2016 /PRNewswire/ -- DRUGSCAN© Pharmaceutical Services, leaders in conducting laboratory-based manipulation and extraction studies, announced today that their scientists will be presenting data at the PAINWeek 2016 conference, from a study they conducted to assess the smoke-ability of opioids. Live Webinar on Best Practices and the FDA’s Abuse-Deterrent Guidance for Innovator and Generic Opioids Horsham, PA (April 27, 2016) – Experts from DrugScan®, PinneyAssociatessm, and INC Research® announced today that they will host a live, complimentary webinar titled, "Understanding the FDA's Abuse-Deterrent Guidance for Innovator and Generic Opioids - The Evolving Pathway for Development and Labeling", on Wednesday May 25, 2016 from 12:00 PM to 1:00 PM EDT. CAT.one™ Manipulation and Extraction Studies Satisfy FDA Requirements for Abuse-Deterrent Opioids Horsham, PA August 5, 2015 – DRUGSCAN© Pharmaceutical Services, a division of DRUGSCAN©, announced the introduction of CAT.one™ laboratory-based manipulation and extraction studies, designed to satisfy the US Food and Drug Administration’s (FDA) requirements for abuse-deterrent opioid pharmaceutical products. PinneyAssociates and DrugScan Collaborate to Offer In Vitro Tamper Testing of Abuse-Deterrent Drugs Bethesda, MD, April 21, 2014 -- PinneyAssociates and DrugScan announce a collaboration to provide in vitro laboratory tamper testing of abuse-deterrent drug products and formulations to pharmaceutical companies developing opioids and other drugs that act on the central nervous system. Phil Dubois to lead Drug Testing Industry Association The Drug and Alcohol Testing Industry Association (DATIA) held its annual meeting last week in Phoenix, Arizona and Phil Dubois took over as the new Chairman of the Board of Directors.